Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Change in Cash (2016 - 2025)

Fennec Pharmaceuticals filings provide 15 years of Change in Cash readings, the most recent being $14.8 million for Q4 2025.

  • On a quarterly basis, Change in Cash rose 208.44% to $14.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.2 million, a 24.03% decrease, with the full-year FY2025 number at $10.2 million, down 24.03% from a year prior.
  • Change in Cash hit $14.8 million in Q4 2025 for Fennec Pharmaceuticals, up from $3.2 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $37.9 million in Q1 2024 to a low of -$13.7 million in Q4 2024.
  • Median Change in Cash over the past 5 years was -$3.0 million (2021), compared with a mean of -$106705.9.
  • The widest YoY moves for Change in Cash: up 804.22% in 2024, down 1673.1% in 2024.
  • Fennec Pharmaceuticals' Change in Cash stood at -$3.0 million in 2021, then plummeted by 102.1% to -$6.0 million in 2022, then skyrocketed by 114.55% to $870000.0 in 2023, then tumbled by 1673.1% to -$13.7 million in 2024, then skyrocketed by 208.44% to $14.8 million in 2025.
  • The last three reported values for Change in Cash were $14.8 million (Q4 2025), $3.2 million (Q3 2025), and -$4.0 million (Q2 2025) per Business Quant data.